Patent 10131907 was granted and assigned to Alnylam Pharmaceuticals on November, 2018 by the United States Patent and Trademark Office.
The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.